Lifecore Biomedical
LFCR
69 hedge funds and large institutions have $132M invested in Lifecore Biomedical in 2023 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 17 increasing their positions, 19 reducing their positions, and 14 closing their positions.
9% more call options, than puts
Call options by funds: $2.05M | Put options by funds: $1.89M
0.06% less ownership
Funds ownership: 65.51% → 65.45% (-0.06%)
8% less funds holding
Funds holding: 75 → 69 (-6)
11% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 19
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
43% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 14
63% less capital invested
Capital invested by funds: $358M → $132M (-$225M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Verition Fund Management
Greenwich,
Connecticut
|
+$2.86M |
| 2 |
GRIM
Greenhaven Road Investment Management
Greenwich,
Connecticut
|
+$2.66M |
| 3 |
Millennium Management
New York
|
+$2.17M |
| 4 |
HT
HAP Trading
New York
|
+$1.5M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$700K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSC
Cove Street Capital
El Segundo,
California
|
-$4.7M |
| 2 |
CCM
Corsair Capital Management
New York
|
-$1.18M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$986K |
| 4 |
Jane Street
New York
|
-$544K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$520K |
LFCR Hedge Fund Activity: Q3 2023 in Review
69 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q3 2023, worth a combined $132M — down 63% from $358M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of LFCR and 8 opened new positions — a net loss of 6 holders — while 19 trimmed existing stakes and 17 added.
The largest buyer was Verition Fund Management, opening a new position worth an estimated $2.86M. The largest seller was Cove Street Capital, cutting an estimated $4.7M.
- 69 institutional investors held Lifecore Biomedical (LFCR) as of Q3 2023, down from 75 in Q2 2023.
- Funds reported $132M of Lifecore Biomedical stock for Q3 2023, down 63% quarter-over-quarter.
- 8 funds opened new Lifecore Biomedical positions in Q3 2023 and 14 closed out, a net change of -6 holders.
- The largest Lifecore Biomedical buyer in Q3 2023 was Verition Fund Management, an estimated $2.86M added.
- The largest Lifecore Biomedical seller in Q3 2023 was Cove Street Capital, an estimated $4.7M sold.
Based on aggregated 13F filings for Q3 2023.